A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1619-1628

  Leijen, Suzanne ^a   Soetekouw, Patricia M M B ^b   Jeffry Evans, T R ^c   Nicolson, Marianne ^d   Schellens, Jan H M ^a,e   Learoyd, Maria ^g   Grinsted, Lynda ^g   Zazulina, Victoria ^g   Pwint, Thinn ^f   Middleton, Mark ^f  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e UTRECHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g ASTRAZENECA   (United Kingdom)

Author keywords

Food effect; MEK 1 2 inhibitor; Phase I; Selumetinib

Indexed keywords

ARRY 142866; DRUG METABOLITE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N DESMETHYLSELUMETINIB; SELUMETINIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BILIARY TRACT CANCER; BLADDER CANCER; BLURRED VISION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ESOPHAGUS CANCER; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FOOD; FOOD DRUG INTERACTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERTENSION; JOINT SWELLING; KIDNEY CANCER; LIVER CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SKIN FISSURE; SOFT TISSUE CANCER; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VITAL SIGN; XEROSTOMIA;

ADULT; AGED; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; FOOD; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MIDDLE AGED; NEOPLASMS;

EID: 82455212125     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1732-7     Document Type: Article

References (28)

1. L Chang M Karin 2001 Mammalian MAP kinase signalling cascades Nature 410 37 40 11242034 10.1038/35065000 1:CAS:528:DC%2BD3MXhvVSgs7k%3D (Pubitemid 32225829)
2. J Downward 2003 Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 11 22 12509763 10.1038/nrc969 1:CAS:528:DC%2BD38XpvVertbo%3D (Pubitemid 37328883)
3. N Ramnath A Adjei 2007 Inhibitors of Raf kinase and MEK signaling Update Cancer Ther 2 111 118 10.1016/j.uct.2007.10.001 10.1016/j.uct.2007.10.001 (Pubitemid 350181652)
4. F Bonnet M Vigneron O Bensaude MF Dubois 1999 Transcription-independent phosphorylation of the RNA polymerase II C-terminal domain (CTD) involves ERK kinases (MEK1/2) Nucleic Acids Res 27 4399 4404 10536148 10.1093/nar/27.22.4399 1:CAS:528:DyaK1MXns1ykurg%3D (Pubitemid 29533180)
5. CR Weinstein-Oppenheimer WL Blalock LS Steelman F Chang JA McCubrey 2000 The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors Pharmacol Ther 88 229 279 11337027 10.1016/S0163-7258(00)00085-1 1:CAS:528:DC%2BD3MXjtFGns7c%3D (Pubitemid 32406054)
6. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6:2209-2219. doi: 10.1158/1535-7163.MCT-07-0231 (Pubitemid 47294749)
7. TC Yeh V Marsh BA Bernat J Ballard H Colwell RJ Evans J Parry D Smith BJ Brandhuber S Gross, et al. 2007 Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor Clin Cancer Res 13 1576 1583 10.1158/1078-0432.CCR-06-1150 17332304 10.1158/1078-0432.CCR-06-1150 1:CAS:528:DC%2BD2sXitlSjtLg%3D (Pubitemid 46450450)
8. NK Haass K Sproesser TK Nguyen R Contractor CA Medina KL Nathanson M Herlyn KS Smalley 2008 The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel Clin Cancer Res 14 230 239 18172275 10.1158/1078-0432.CCR-07-1440 1:CAS:528:DC%2BD1cXoslGr (Pubitemid 351378000)
9. R Dummer C Robert PB Chapman JA Sosman M Middleton L Bastholt K Kemsley MV Cantarini C Morris JM Kirkwood 2008 AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study J Clin Oncol (Meeting Abstracts) 26 9033
10. Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC (2011) A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. (in press). doi: 10.1007/s10637-011-9687-4
11. Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, Kim TY, Pover GM, Morris CD, Douillard JY (2010) A phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs. doi: 10.1007/s10637-010-9392-8
12. JD Hainsworth CL Cebotaru V Kanarev TE Ciuleanu D Damyanov P Stella H Ganchev G Pover C Morris V Tzekova 2010 A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens J Thorac Oncol 5 1630 1636 10.1097/JTO. 0b013e3181e8b3a3 20802351 10.1097/JTO.0b013e3181e8b3a3
13. T Bekaii-Saab MA Phelps X Li M Saji L Goff JS Kauh BH O'Neil S Balsom C Balint R Liersemann, et al. 2011 Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers J Clin Oncol 29 2357 2363 10.1200/JCO.2010.33.9473 21519026 10.1200/JCO.2010.33.9473 1:CAS:528:DC%2BC3MXovFKqsbc%3D
14. AA Adjei RB Cohen W Franklin C Morris D Wilson JR Molina LJ Hanson L Gore L Chow S Leong, et al. 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers J Clin Oncol 26 2139 2146 10.1200/JCO.2007.14.4956 18390968 10.1200/JCO.2007.14.4956 1:CAS:528:DC%2BD1cXms1OrtL8%3D
15. U Banerji DR Camidge HM Verheul R Agarwal D Sarker SB Kaye IM Desar JN Timmer-Bonte SG Eckhardt KD Lewis, et al. 2010 The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer Clin Cancer Res 16 1613 1623 10.1158/1078-0432.CCR-09-2483 20179232 10.1158/1078-0432.CCR-09-2483 1:CAS:528:DC%2BC3cXisFSisLY%3D
16. JM Custodio CY Wu LZ Benet 2008 Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption Adv Drug Deliv Rev 60 717 733 18199522 10.1016/j.addr.2007.08.043 1:CAS:528:DC%2BD1cXitVOmsr0%3D
17. RZ Harris GR Jang S Tsunoda 2003 Dietary effects on drug metabolism and transport Clin Pharmacokinet 42 1071 1088 14531721 10.2165/00003088-200342130- 00001 1:CAS:528:DC%2BD3sXpsF2ls70%3D (Pubitemid 37357646)
18. BN Singh 1999 Effects of food on clinical pharmacokinetics Clin Pharmacokinet 37 213 255 10511919 10.2165/00003088-199937030-00003 1:CAS:528:DyaK1MXmsFKrsL0%3D (Pubitemid 29452756)
19. Chow LQM, Eckhardt SG, Reid JM, Molina J, Hanson L, Piens J et al (2005) A first in human dose-ranging study to assess the pharmacokinetics, pharmacodynamics, and toxicities of the MEK inhibitor ARRY-142886 (AZD6244) in patients with advanced solid malignancies. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics abstract C162
20. PG Welling 1996 Effects of food on drug absorption Annu Rev Nutr 16 383 415 8839932 10.1146/annurev.nu.16.070196.002123 1:CAS:528:DyaK28XksFKru7w%3D
21. CY Lui GL Amidon RR Berardi D Fleisher C Youngberg JB Dressman 1986 Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans J Pharm Sci 75 271 274 3701609 10.1002/jps.2600750313 1:CAS:528:DyaL28Xhsl2ks74%3D (Pubitemid 16136927)
22. WN Charman CJ Porter S Mithani JB Dressman 1997 Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH J Pharm Sci 86 269 282 9050793 10.1021/js960085v 1:CAS:528:DyaK2sXhtVGit7Y%3D (Pubitemid 27113759)
23. PM LoRusso AA Adjei M Varterasian S Gadgeel J Reid DY Mitchell L Hanson P DeLuca L Bruzek J Piens, et al. 2005 Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies J Clin Oncol 23 5281 5293 10.1200/JCO.2005.14.415 16009947 10.1200/JCO.2005.14.415 1:CAS:528:DC%2BD2MXpslOrtL8%3D (Pubitemid 46206982)
24. J Rinehart AA Adjei PM LoRusso D Waterhouse JR Hecht RB Natale O Hamid M Varterasian P Asbury EP Kaldjian, et al. 2004 Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J Clin Oncol 22 4456 4462 10.1200/JCO.2004.01.185 15483017 10.1200/JCO.2004.01.185 1:CAS:528: DC%2BD2cXhtFWqt77L (Pubitemid 41185111)
25. PJ Roberts CJ Der 2007 Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 3291 3310 17496923 10.1038/sj.onc.1210422 1:CAS:528:DC%2BD2sXlt1Wktb4%3D (Pubitemid 46763022)
26. PM LoRusso SS Krishnamurthi JJ Rinehart LM Nabell L Malburg PB Chapman SE DePrimo S Bentivegna KD Wilner W Tan, et al. 2010 Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers Clin Cancer Res 16 1924 1937 10.1158/1078-0432. CCR-09-1883 20215549 10.1158/1078-0432.CCR-09-1883 1:CAS:528: DC%2BC3cXjtFyhurk%3D
27. EB Haura AD Ricart TG Larson PJ Stella L Bazhenova VA Miller RB Cohen PD Eisenberg P Selaru KD Wilner, et al. 2010 A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer Clin Cancer Res 16 2450 2457 20332327 10.1158/1078-0432.CCR-09-1920 1:CAS:528:DC%2BC3cXkslSlsbo%3D
28. L Lee H Niu R Rueger Y Igawa J Deutsch N Ishii S Mu Y Sakamoto R Busse-Reid C Gimmi, et al. 2009 The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker Clin Cancer Res 15 7368 7374 19934286 10.1158/1078-0432.CCR-09-1696 1:CAS:528:DC%2BD1MXhsFSnu7rJ